ATE314394T1 - Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta - Google Patents

Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta

Info

Publication number
ATE314394T1
ATE314394T1 AT94925878T AT94925878T ATE314394T1 AT E314394 T1 ATE314394 T1 AT E314394T1 AT 94925878 T AT94925878 T AT 94925878T AT 94925878 T AT94925878 T AT 94925878T AT E314394 T1 ATE314394 T1 AT E314394T1
Authority
AT
Austria
Prior art keywords
beta
tgf
latent
effective
tsp
Prior art date
Application number
AT94925878T
Other languages
English (en)
Inventor
Joanne E Murphy-Ullrich
David D Roberts
Henry C Krutzsch
Stacey Schultz-Cherry
Original Assignee
Uab Research Foundation
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, Us Gov Health & Human Serv filed Critical Uab Research Foundation
Application granted granted Critical
Publication of ATE314394T1 publication Critical patent/ATE314394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94925878T 1993-08-13 1994-08-12 Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta ATE314394T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10612093A 1993-08-13 1993-08-13
US23816994A 1994-05-04 1994-05-04
PCT/US1994/009193 WO1995005191A1 (en) 1993-08-13 1994-08-12 METHODS AND COMPOSITIONS FOR STIMULATING AND INHIBITING TGF-β ACTIVITY

Publications (1)

Publication Number Publication Date
ATE314394T1 true ATE314394T1 (de) 2006-01-15

Family

ID=26803316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925878T ATE314394T1 (de) 1993-08-13 1994-08-12 Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta

Country Status (8)

Country Link
US (1) US6384189B1 (de)
EP (1) EP0716609B1 (de)
JP (1) JPH09505555A (de)
AT (1) ATE314394T1 (de)
AU (1) AU697624B2 (de)
CA (1) CA2169360A1 (de)
DE (1) DE69434593D1 (de)
WO (1) WO1995005191A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
WO1998041542A1 (en) * 1997-03-17 1998-09-24 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU741061B2 (en) * 1997-08-13 2001-11-22 Kyowa Hakko Kogyo Co. Ltd. Novel vascular smooth muscle cell growth factor
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6121236A (en) * 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9915311D0 (en) * 1999-06-30 1999-09-01 Isis Innovation Modulation of dendritic cell maturation
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
ITMI20010995A1 (it) 2001-05-15 2002-11-15 Getters Spa Dispensatori di cesio e processo per il loro uso
WO2004101598A2 (en) * 2003-05-09 2004-11-25 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
CN101267829A (zh) * 2005-06-24 2008-09-17 卡迪拉保健公司 血小板反应蛋白-1的衍生肽以及治疗方法
US9614220B2 (en) 2007-01-29 2017-04-04 Umicore Doped and island-covered lithium cobaltite oxides
AU2009279676C1 (en) * 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
EP2836591B1 (de) 2012-04-09 2018-06-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Verfahren zur erzeugung pluripotenter und multipotenter zellen
KR101594032B1 (ko) * 2012-08-23 2016-02-15 강원대학교산학협력단 염증 또는 피부노화의 예방 또는 치료용 약학 조성물 및 염증 또는 피부노화 개선용 화장료 조성물
AU2014244083B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
US9353149B2 (en) * 2013-05-10 2016-05-31 Southern Research Institute Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity
FR3024364B1 (fr) 2014-07-31 2016-09-02 Neuronax Oligopeptides particuliers comme medicaments anti-angiogeniques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG64368A1 (en) * 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5028425A (en) * 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5190918A (en) 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5674503A (en) * 1990-07-24 1997-10-07 University Of Victoria Peptides capable of eliciting an immune response to leishmaniasis and methods of using the same
US5824647A (en) * 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides

Also Published As

Publication number Publication date
AU697624B2 (en) 1998-10-15
EP0716609A1 (de) 1996-06-19
AU7565294A (en) 1995-03-14
CA2169360A1 (en) 1995-02-23
EP0716609A4 (de) 1998-01-07
EP0716609B1 (de) 2005-12-28
DE69434593D1 (de) 2006-02-02
WO1995005191A1 (en) 1995-02-23
US6384189B1 (en) 2002-05-07
JPH09505555A (ja) 1997-06-03

Similar Documents

Publication Publication Date Title
ATE314394T1 (de) Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta
DE69636997D1 (de) HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
ATE529109T1 (de) Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
ATE277612T1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE69924615D1 (de) Thymosin beta 4 stimuliert wundheilung
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE69732367D1 (de) Verwendung eines oestrogens zur verhütung und behandlung von ischaemischer schädigung
ATE396151T1 (de) Elektrochemische behandlung von mit stickstoffhaltigen verbindungen verunreinigtem wasser
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
ATE217514T1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE226084T1 (de) Wundheilung und behandlung von fibrose
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DK0671909T3 (da) Syndecanstimulering af cellulær differentiering
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE227991T1 (de) Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
ATE275414T1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
ATE216885T1 (de) Verwendung von penciclovir zur behandlung von postherpetischer neuralgie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties